Stem Cell Facility Warned for ‘Objectionable Conditions’

Drug Industry Daily
A A
The FDA sent a warning letter listing a slew of violations to StemGenex Biologic Laboratories, following a January 16-26 inspection of its San Diego, California, facility.

To View This Article:

Login

Subscribe To Drug Industry Daily